Author: Customer Service

Additional Results from ACACIA-HCM Demonstrate Improvements in Cardiac Structure and Diastolic Function in Patients with Non-Obstructive HCM New Analysis of MAPLE-HCM Finds Aficamten Outperformed Metoprolol Across Pre-Trial Treatment Groups in Patients with Obstructive HCM SOUTH SAN FRANCISCO, Calif., Aug. 29, 2026 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional results from ACACIA-HCM (Assessment Comparing Aficamten to Placebo on Cardiac Endpoints In Adults with Non-Obstructive HCM) and MAPLE-HCM (Metoprolol vs Aficamten in Patients with LVOT Obstruction on Exercise Capacity in HCM) were presented in a Late Breaking Clinical Session at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany and simultaneously published in Circulation and the Journal of the American...

In patients with a baseline 6MWD below the trial median of 333 meters, treatment with TNX-103 resulted in a 26.3-meter improvement compared to placebo (p = 0.0112) In the same patient population, TNX-103 produced a 47% reduction in NT-proBNP (p < 0.0001) and a 4.9 mmHg reduction in RVSP (p = 0.009) compared to placebo With full statistics analysis now complete, Company confirms TNX-103’s biological effects include marked reductions in pulmonary artery pressure and NT-proBNP, a biomarker reflecting increased cardiac wall stress. Results will inform protocol population enrichment and changes to overall registrational path CHAPEL HILL, N.C., Aug. 29, 2026 (GLOBE NEWSWIRE) — Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”) today announced that additional results from the Phase 3 LEVEL clinical...

VANCOUVER, British Columbia, Aug. 28, 2026 (GLOBE NEWSWIRE) — Zacatecas Silver Corp. (TSXV: ZAC | OTCQB: ZCTSF | FRA: 7TV) (“Zacatecas Silver” or the “Company”) is pleased to announce that it has closed the second and final tranche (the “Second Tranche”) of its previously announced non-brokered private placement (the “Offering”, see news release dated July 14, 2026 and July 29, 2026) by issuing 14,639,941 Units at $0.07 per Unit for gross proceeds of $1,024,795.87. Under the entire Offering, the Company issued a total of 35,714,142 Units at $0.07 per Unit for gross proceeds of $2,499,989.94. Each Unit consists of one common share of the Company and one Common Share purchase warrant (each, a “Warrant”). Each Warrant will entitle the holder to purchase one additional Common Share at an exercise price of $0.09 for a period of...

CEO Jonathan Cohen to Detail the Company’s Strongest Quarterly Performance Since Commercial Launch of Multi-Cancer Early Detection Testing, Key Takeaways from the Next Generation Dx Summit, and Path to Broader Commercial Adoption Webinar to Be Held Wednesday, September 2, 2026 at 2:00 p.m. Eastern Time; Registration Is Now Open GAITHERSBURG, Md., Aug. 28, 2026 (GLOBE NEWSWIRE) — 20/20 BioLabs, Inc. (Nasdaq: AIDX) (“20/20 BioLabs” or the “Company”), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that its previously announced investor webinar on Wednesday, September 2, 2026 has been rescheduled to 2:00 p.m. Eastern time. The webinar was previously scheduled to begin at 12:00 p.m. Eastern time on the same date. Jonathan Cohen,...

VANCOUVER, British Columbia, Aug. 28, 2026 (GLOBE NEWSWIRE) — Sable Resources Ltd. (“Sable” or the “Company”) (TSXV:SAE | OTCQB:SBLRF) announces that the Company has granted an aggregate of 650,000 options to purchase common shares of the Company to directors, officers, employees and consultants in accordance with the Company’s stock option plan.  The options granted are exercisable at $0.55 for a period of five years. ABOUT SABLE RESOURCES LTD. Sable is a well-funded junior grassroots explorer focused on the discovery of Tier-One new precious metal and copper projects through systematic exploration in endowed terranes located in favorable, established mining jurisdictions. Sable’s focus is on developing its large portfolio of new Greenfields projects to resource level.  Sable is actively exploring...

– Continued execution of transformation strategy drives commercial, manufacturing and pipeline progress – PrePsia™ patent portfolio expands to nine granted U.S. and European patents – Company issues update on Nasdaq listing DUBLIN, Aug. 28, 2026 (GLOBE NEWSWIRE) — Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, today provided an update on key developments across its diagnostics business, highlighting continued commercial progress, operational transformation and diagnostic pipeline advancement. Strengthening Commercial Leadership in Europe Trinity Biotech is pleased to announce that Jordi Romero has joined the Company as Head of Commercial Operations – Europe. Mr. Romero brings extensive experience in diagnostic...

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, Aug. 28, 2026 (GLOBE NEWSWIRE) — Traction Uranium Corp. (CSE: TRAC) (OTC: TRCTF) (FRA: Z1K) (the “Company” or “Traction”) is pleased to announce that it has closed its previously announced non-brokered private placement of units of the Company (each, a “Unit“) at a price of C$0.95 per Unit, issuing 789,500 Units for aggregate gross proceeds of C$ $750,025.00 (the “Offering“). Each Unit consists of one common share of the Company issued as a “flow-through share” within the meaning of the Income Tax Act (Canada) (the “Tax Act”) (each, an “FT Share“) and one-half of one transferable common share purchase warrant of the Company (each whole warrant, a “Warrant“)....

CALGARY, Alberta, Aug. 28, 2026 (GLOBE NEWSWIRE) — Northern Discovery Metals Inc. (CSE: NOR) (FSE: M1V0) (“Northern Discovery” or the “Company”) announces that it has appointed Independent Trading Group, Inc. (Address: 420, 33 Yonge Street, Toronto, ON, Canada, M5E 1G4; Website: www.itg84.com; Contact: Chris Kaplan; Email: chriskaplan@itg84.com) (“ITG”) as a market maker for its common shares traded on the Canadian Securities Exchange (the “CSE”). The agreement with ITG is for an initial term of one month and will renew for additional one-month terms unless terminated by either party with 30 days’ notice. There are no performance factors contained in the agreement and ITG will not receive shares or options as compensation. ITG and the Company are unrelated and unaffiliated entities and at the time of the agreement, neither...